Tatva Chintan Pharma Chem 관리
관리 기준 확인 3/4
We currently do not have sufficient information about the CEO.
주요 정보
Chintan Shah
최고 경영자
₹13.4m
총 보상
| CEO 급여 비율 | 25.0% |
| CEO 임기 | 28.4yrs |
| CEO 소유권 | 23.8% |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 16.1yrs |
최근 관리 업데이트
Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26
Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹176m |
| Jun 30 2024 | n/a | n/a | ₹261m |
| Mar 31 2024 | ₹13m | ₹3m | ₹304m |
| Dec 31 2023 | n/a | n/a | ₹377m |
| Sep 30 2023 | n/a | n/a | ₹459m |
| Jun 30 2023 | n/a | n/a | ₹452m |
| Mar 31 2023 | ₹17m | ₹5m | ₹455m |
| Dec 31 2022 | n/a | n/a | ₹460m |
| Sep 30 2022 | n/a | n/a | ₹572m |
| Jun 30 2022 | n/a | n/a | ₹825m |
| Mar 31 2022 | ₹17m | ₹5m | ₹959m |
| Dec 31 2021 | n/a | n/a | ₹995m |
| Sep 30 2021 | n/a | n/a | ₹976m |
| Jun 30 2021 | n/a | n/a | ₹687m |
| Mar 31 2021 | ₹14m | n/a | ₹523m |
| Mar 31 2020 | ₹14m | n/a | ₹378m |
| Mar 31 2019 | ₹14m | n/a | ₹205m |
보상 대 시장: Chintan's total compensation ($USD159.23K) is about average for companies of similar size in the Indian market ($USD179.47K).
보상과 수익: Chintan's compensation has been consistent with company performance over the past year.
CEO
Chintan Shah (51 yo)
28.4yrs
테뉴어
₹13,390,870
보상
Mr. Chintan Nitinkumar Shah is the Managing Director and Chairman at Tatva Chintan Pharma Chem Limited and its Executive Director since June 12, 1996. He holds a bachelor’s degree in engineering, with a sp...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & MD | 28.4yrs | ₹13.39m | 23.84% ₹ 4.8b | |
| Whole Time Director | 28.4yrs | ₹13.39m | 24.01% ₹ 4.8b | |
| Whole Time Director | 28.4yrs | ₹13.39m | 24% ₹ 4.8b | |
| Non Executive Independent Director | 3.8yrs | ₹265.00k | 데이터 없음 | |
| Non Executive Independent Director | 3.8yrs | ₹285.00k | 데이터 없음 | |
| Non Executive Independent Director | 3.8yrs | ₹22.50k | 데이터 없음 |
16.1yrs
평균 재임 기간
51.5yo
평균 연령
경험이 풍부한 이사회: TATVA's board of directors are seasoned and experienced ( 16.1 years average tenure).